Cargando…
A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML
BACKGROUND: Myeloid and lymphoid malignancies associated with chimeric FGFR1 kinases are the hallmark of stem cell leukemia and lymphoma syndrome (SCLL). In all cases, FGFR1 kinase is constitutively phosphoactivated as a result of chromosome translocations, which lead to acquisition of dimerization...
Autores principales: | Cai, Baohuan, Liu, Yun, Chong, Yating, Mori, Stephanie Fay, Matsunaga, Atsuko, Zhang, Hualei, Fang, Xuexiu, Chang, Chang-Sheng, Cowell, John K., Hu, Tianxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336057/ https://www.ncbi.nlm.nih.gov/pubmed/35906694 http://dx.doi.org/10.1186/s12943-022-01628-3 |
Ejemplares similares
-
IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies
por: Cai, Baohuan, et al.
Publicado: (2021) -
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022) -
Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome
por: Liu, Yun, et al.
Publicado: (2020) -
Targeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models
por: Wu, Qing, et al.
Publicado: (2016) -
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)